查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1634202

全球氧化壓力檢測市場 - 2025 - 2033

Global Oxidative Stress Assay Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 157 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球氧化壓力檢測市場規模達11.8億美元，預計2032年將達到19億美元，2025-2032年預測期間複合年成長率為9.7%。

氧化壓力測定通常稱為止痛藥，是一類旨在緩解疼痛的藥物。它們的作用是阻斷體內的疼痛訊號或改變大腦解釋這些訊號的方式。這些藥物有多種形式，從非處方藥到處方藥。這些藥物可以口服、腸胃外和局部服用。

市場動態：

驅動程式和限制

提高對疾病發病機制中氧化壓力的認知

對疾病發病機制中氧化壓力的認知不斷提高是氧化壓力檢測市場成長的主要驅動力。隨著科學研究不斷揭示氧化壓力在各種慢性疾病（包括癌症、心血管疾病、糖尿病和神經退化性疾病）的發生和發展中所起的關鍵作用，人們越來越認知到它在整體健康管理中的重要性。這種認知的加深導致對診斷工具的需求激增，例如可以準確測量和監測患者氧化損傷的氧化壓力測定。

透過識別氧化壓力的早期跡象，這些檢測為疾病機制提供了寶貴的見解，幫助醫療保健提供者在預防、治療和疾病管理方面做出更明智的決策。因此，人們對氧化壓力在疾病發病機制中的作用的認知不斷提高，推動了這些檢測方法在研究和臨床環境中的更多採用，從而促進了市場的擴張。

替代方法帶來的競爭加劇

由於替代方法的出現為研究人員和臨床醫生提供了更具吸引力的選擇，全球氧化壓力檢測市場預計將面臨挑戰。隨著診斷技術的進步，生物標記檢測和成像技術等替代方法變得越來越流行。這些方法可以間接或透過不同的生物途徑評估氧化壓力，與傳統的氧化壓力測定相比，通常可以縮短週轉時間並簡化工作流程。這種對替代測試方法的偏好轉變可能會轉移人們對傳統氧化壓力測定的注意力和資源，從而使氧化壓力測定市場難以保持其成長勢頭。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 提高對疾病發病機制中氧化壓力的認知
    • 限制
      • 替代方法帶來的競爭加劇
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 專利分析
  • 監管分析
  • SWOT分析
  • 未滿足的需求

第 6 章：依產品

  • 耗材
  • 儀器儀表
  • 套件
  • 服務

第 7 章：按測試類型

  • 間接測定
  • 抗氧化能力測定
  • 基於酵素的測定
  • 基於活性氧 (ROS) 的檢測

第 8 章：按技術

  • 酵素連結免疫吸附測定法 (ELISA)
  • 色譜法
  • 流式細胞儀
  • 顯微鏡檢查
  • 高內涵篩選
  • 無標記檢測技術

第 9 章：依疾病類型

  • 心血管疾病
  • 糖尿病
  • 慢性阻塞性肺病（COPD）
  • 癌症
  • 氣喘

第 10 章：按最終用戶

  • 製藥公司
  • 生技公司
  • 臨床實驗室
  • 學術及研究機構
  • 合約研究組織
  • 其他

第 11 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 12 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 13 章：公司簡介

  • Abcam, plc.
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Enzo Biochem, Inc.
  • AMS Biotechnology Ltd.
  • Cell Biolabs, Inc.
  • Promega Corporation
  • Cayman Chemical
  • Eagle Biosciences, Inc.
  • Arbor Assays
  • Kamiya Biomedical Company
  • Genox Corporation

第 14 章：附錄

第 15 章：聯絡我們

簡介目錄
Product Code: BT4826

The global oxidative stress assay market reached US$ 1.18 billion in 2024 and is expected to reach US$ 1.9 billion by 2032, growing at a CAGR of 9.7% during the forecast period 2025-2032.

Oxidative Stress Assays, commonly known as painkillers, are a class of drugs designed to relieve pain. They work by blocking pain signals in the body or by altering the way the brain interprets those signals. These medications come in various forms, ranging from over-the-counter to prescription medications. These medications can be taken orally, parenterally, and topically.

Market Dynamics: Drivers & Restraints

Increasing awareness of oxidative stress in disease pathogenesis

Increasing awareness of oxidative stress in disease pathogenesis is a major driver for the growth of the oxidative stress assay market. As scientific research continues to uncover the pivotal role oxidative stress plays in the development and progression of various chronic diseases, including cancer, cardiovascular conditions, diabetes, and neurodegenerative disorders, there is a growing recognition of its significance in overall health management. This increased understanding has led to a surge in demand for diagnostic tools, such as oxidative stress assays, that can accurately measure and monitor oxidative damage in patients.

By identifying early signs of oxidative stress, these assays provide valuable insights into disease mechanisms, helping healthcare providers make more informed decisions regarding prevention, treatment, and disease management. As a result, the increasing awareness of oxidative stress's role in disease pathogenesis is fueling greater adoption of these assays in both research and clinical settings, contributing to the market's expansion.

Rising competition from alternative methods

The global oxidative stress assays market is expected to face challenges due to the emergence of alternative methods that offer researchers and clinicians more appealing options. As diagnostic technologies advance, alternatives such as biomarker assays and imaging techniques are becoming increasingly popular. These methods can evaluate oxidative stress indirectly or through different biological pathways, often resulting in faster turnaround times and simpler workflows compared to traditional oxidative stress assays. This shift in preference towards alternative testing methods can divert attention and resources away from conventional oxidative stress assays, making it difficult for the oxidative stress assays market to maintain its growth momentum.

Segment Analysis

The global oxidative stress assay market is segmented based on product, test type, technology, disease type, end-user, and region.

Type:

Indirect assay segment is expected to dominate the global oxidative stress assay market share

The indirect assay segment is anticipated to lead the oxidative stress market, driven by several compelling advantages that make them highly appealing for both clinical and research applications. Indirect assays assess oxidative stress by detecting biomarkers, such as lipid peroxides, protein carbonyls, and DNA adducts, which are byproducts of oxidative damage. These assays are typically simpler, more cost-effective, and easier to conduct than direct assays that measure reactive oxygen species (ROS) directly. Consequently, indirect assays are frequently utilized in routine testing and large-scale studies, where affordability and ease of use are essential.

Additionally, indirect assays are particularly valuable for monitoring chronic conditions, as they can provide insights into long-term oxidative damage. This capability is critical for assessing the progression of diseases associated with oxidative stress. The growing preference for biomarker-based diagnostics, combined with the increasing adoption of these assays, is expected to propel their market share.

Furthermore, innovations in reagent development and the automation of testing processes are improving the sensitivity, throughput, and scalability of indirect assays, further solidifying their dominant position in the market. With their affordability, ease of use, and reliable results, indirect assays are well-positioned to drive the continued growth of the oxidative stress testing market.

Geographical Analysis

North America is expected to hold a significant position in the global oxidative stress assay market share

North America is expected to maintain a dominant position in the oxidative stress assay market due to several key factors. The region has a high level of investment in medical research, which fosters the development and adoption of advanced diagnostic tools, including oxidative stress assays. The presence of major pharmaceutical and biotechnology companies in the U.S. and Canada also contributes to the rapid development and commercialization of innovative assays for oxidative stress measurement.

Additionally, the rising prevalence of chronic diseases, such as cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders, in North America is driving demand for reliable diagnostic tools that can monitor oxidative stress, a key factor in the progression of these diseases. As the focus on personalized medicine and preventative healthcare grows, the demand for biomarkers and assays to assess oxidative damage is expected to increase, further fueling market growth.

Moreover, North America benefits from strong regulatory frameworks and well-established research and clinical standards, making it easier to introduce and adopt new assays. The region's advanced technological capabilities also support the continuous improvement of assay sensitivity and accuracy, providing a competitive edge. With increasing awareness of oxidative stress's role in disease pathogenesis and ongoing advancements in diagnostic technology, North America is poised to remain a leading market for oxidative stress assays in the coming years.

Competitive Landscape

The major global players in the oxidative stress assay market include Bayer AG, Teva Pharmaceuticals USA, Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin, Cipla, Sanofi, AdvaCare Pharma, Wellona Pharma, and Montage Laboratories Pvt. Ltd. among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Oxidative Stress Assays market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by Technology
  • 3.4. Snippet by Disease Type
  • 3.5. Snippet by End-user
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness of oxidative stress in disease pathogenesis
    • 4.1.2. Restraints
      • 4.1.2.1. Rising competition from alternative methods
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. Consumables*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Instruments
  • 6.4. Kits
  • 6.5. Services

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 7.1.2. Market Attractiveness Index, By Test Type
  • 7.2. Indirect Assays*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Antioxidant Capacity Assays
  • 7.4. Enzyme-based Assays
  • 7.5. Reactive Oxygen Species (ROS)-based Assays

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Enzyme-linked Immunosorbent Assay (ELISA)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Chromatography
  • 8.4. Flow Cytometry
  • 8.5. Microscopy
  • 8.6. High-Content Screening
  • 8.7. Label-free Detection Technology

9. By Disease Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.1.2. Market Attractiveness Index, By Disease Type
  • 9.2. Cardiovascular Disease*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diabetes
  • 9.4. Chronic Obstructive Pulmonary Disease (COPD)
  • 9.5. Cancer
  • 9.6. Asthma

10. By End-user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.1.2. Market Attractiveness Index, By End-user
  • 10.2. Pharmaceutical Companies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Biotechnology Companies
  • 10.4. Clinical Laboratories
  • 10.5. Academic & Research Institutes
  • 10.6. Contract Research Organizations
  • 10.7. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Spain
      • 11.3.8.5. Italy
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. South Korea
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abcam, plc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Enzo Biochem, Inc.
  • 13.3. AMS Biotechnology Ltd.
  • 13.4. Cell Biolabs, Inc.
  • 13.5. Promega Corporation
  • 13.6. Cayman Chemical
  • 13.7. Eagle Biosciences, Inc.
  • 13.8. Arbor Assays
  • 13.9. Kamiya Biomedical Company
  • 13.10. Genox Corporation

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services

15. Contact Us